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ABSTRACT 
 
Aims: To demonstrate the efficacy of several small molecular weight compounds having hydrazide 
groups, for inhibiting the growth of Mycobacterium tuberculosis. To show these same compounds 
have favorable drug-likeness properties.   
Study Design: To synthesize tuberculostats and test their antibacterial activity in-vitro. 
Place and Duration of Study: University of Nebraska, Durham Science Center, 6001 Dodge 
Street, Omaha NE 68182, and Texas A&M Health Science Center, Department of Microbial 
Pathogenesis and Immunology, 8447 State Hwy 47, Medical Research and Education Building, 
Room #3012, Bryan, TX 7780. From January 2015 to June 2015. 
Methodology: Hydrazide groups were formed by covalently bonding hydrazine onto small 
molecules having a single aromatic ring by utilizing microwave excitation and evaluating for 
antibacterial activity. These compounds were placed into tissue culture media at various 
Original Research Article 
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concentrations and then tuberculosis bacteria were added to determine the level of growth 
inhibition. Growth inhibition of the bacteria was measured as a function of compound concentration 
for assessment and comparison. 
Results: Compounds A, B, C, and D carry hydrazide groups with various substituents that are 
bonded to a single aromatic ring. All four compounds show zero violations of Rule of 5, indicating 
favorable absorption and membrane permeation. All four compounds showed greater than 85% 
growth inhibition of bacteria at concentrations below 50 micrograms per milliliter, while assayed by 
colony forming units and luminescence. Values of Log BB suggests compounds A and C will have 
greater penetration into the central nervous system than isoniazid.  
Conclusion: These four hydrazide compounds induced substantial inhibition of bacterial growth.  
Microwave excitation for the synthesis of hydrazide compounds is effective. These compounds 
have favorable drug-likeness properties and are highly effective inhibiting growth of Mycobacterium 
tuberculosis. 
 
 
Keywords: Tuberculosis; TB; hydrazide; Mycobacterium tuberculosis; tuberculostatic. 
 
ABBREVIATIONS 
  
Term: TB, tuberculosis; A2, Angstroms2; A3, Angstroms3; SMILES, simplified molecular-input line-entry 
system; IUPAC, International Union of Pure and Applied Chemistry; MDR-TB, multi-drug resistant 
Mycobacterium tuberculosis; M/XDR-TB, extensively drug resistant Mycobacterium tuberculosis; 
TDR-TB, totally drug resistant tuberculosis; GPCR, G-protein-coupled receptors; CFU, colony forming 
units; CNS, central nervous system. 
 
1. INTRODUCTION  
 
Multi-drug resistant Mycobacterium tuberculosis 
(MDR-TB) and extensively drug resistant 
Mycobacterium tuberculosis (M/XDR-TB) is a 
substantial challenge for clinicians and                
public health workers worldwide [1]. The lack                 
of new effective drugs, improper regimens,                  
and unreliable drug susceptibility testing is 
believed to have added to the problem [1].                 
MDR-TB patients having localized disease,               
may benefit from utilization of surgery as an 
adjunct to chemotherapy [1]. Summation in 2005, 
indicated that an estimated 8.8 million new     
cases of active tuberculosis were reported and 
leading to an estimated 1.6 million deaths per 
year [2].   
 
Tuberculosis (TB) infections of the central 
nervous system (CNS) accounts for about 1%                 
of all cases of tuberculosis and carries a              
high mortality level as well as causing 
neurological morbidity [2,3]. Tuberculosis 
infection of the CNS is a devastating clinical 
manifestations of tuberculosis. Often described 
as meningitis, encephalitis is within the spectrum 
of clinical manifestations [4]. In a previously 
conducted epidemiological study of 
extrapulmonary tuberculosis within the United 
States, involvement of the CNS was noted in 5     
to 10% of all extrapulmonary tuberculosis                
cases [2].  
Treatment for M. tuberculosis meningitis includes 
isoniazid, rifampicin, pyrazinamide and 
ethambutol for a period of two months, which is 
then followed by isoniazid and rifampicin alone 
for a further ten months [5]. Interestingly, the 
administration of aspirin may actually reduce or 
even delay mortality [6]. TB meningitis is known 
to occur more frequently in children and 
especially children less than one year of age [7].   
 
Totally drug-resistant tuberculosis (TDR-TB) has 
been reported in Iran, India and South Africa [8]. 
TDR-TB is most commonly described as an 
incidence that is resistance to all first- line drugs 
(isoniazid, rifampicin, pyrazinamide, ethambutol, 
and streptomycin) and second-line drugs 
administered to treat TB [8]. Adjunct TB 
therapies, including repurposing of drugs that 
target biologically molecular pathways, may 
achieve better clinical outcomes in combination 
with the standard chemotherapy [8]. Having 
general symptomatic signs of fever, chills, night 
sweats, appetite loss, and fatigue, cases of 
pulmonary tuberculosis may infect any part of the 
body where it is considered to be extrapulmonary 
TB which may coexist with pulmonary TB as well 
[9,10].  
 
A latent tuberculosis infection is defined in a 
patient that is infected with Mycobacterium 
tuberculosis but has no active tuberculosis [11]. 
Although latent tuberculosis is not considered 
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contagious, approximately 10% of these patients 
will go on to develop active tuberculosis [11].  
Identification and treatment of individuals having 
latent TB is an important aspect of controlling the 
disease, however treatment regimens generally 
need to be administered for several months [11]. 
 
Clearly, new drug designs continuing studies are 
well advised in the face of the threat of MDR-TB, 
M/XDR-TB, and TDR-TB. This study presents 
novel drug designs which apply the hydrazide 
group found in the first-line drug isoniazid, to an  
aromatic ring scaffolding that will modify 
molecular properties favorably for oral 
administration and penetration into the CNS.  
This approach, to beneficially modify molecular 
properties, has been shown to be highly 
efficacious for inhibiting M. tuberculosis [12-15], 
Staphylococcus aureus [16-18], and Escherichia 
coli [19-22]. The novel hydrazide compounds 
presented here are shown to significantly inhibit 
the growth of M. tuberculosis and favorable drug-
likeness. 
 
This study presents the efficacy of several small 
hydrazide compounds for inhibiting the growth of 
Mycobacterium tuberculosis. These same 
compounds have favorable drug-likeness 
properties. 
 
2. METHODOLOGY   
 
2.1 Reagents and Instrumentation 
 
All reagents were obtained from Aldrich-Sigma 
Company (P.O. Box 2060, Milwaukee, WI 53201 
USA). Infrared spectroscopy can be 
accomplished in a Mattson Galaxy FTIR in a 
dimethyl sulfoxide solvent that has been 
previously dried over molecular sieves to remove 
water prior to obtaining spectra. 
 
2.2 Molecular Modeling and Numerical 
Analysis 
 
Molecular modeling (2-D and 3-D) were 
accomplished by ChemSketch version 12.01 
ACD/Labs Release: 12.00 (90 Adelaide Street 
West, Toronto, Ontario M5H 3V9, Canada) 
Molecular properties were determined by utilizing 
Molinspiration (Liscie Udolie 2, SK-841 04 
Bratislava, Slovak Republic). Correlation statistic 
by Pearson r and other statistical analysis was 
accomplished by Microsoft Office Excel 2007 or 
PAST version 2.06 (copyright Hammer and 
Harper 1999-2011). Molecular dipole values 
were determined by package Gaussian-
GaussView 5.0 (Gaussian Inc., 340 Quinnipiac 
St. Bldg. 40, Wallingford CT 06492 USA).  
 
2.3 Bacterial Culture 
 
2.3.1 Strain of bacteria 
 
Mycobacterium tuberculosis strain CDC1551 wild 
type carrying vector plasmid pJDC174 and BCG 
carrying the same vector expressing a codon-
optimized click beetle red gene (CBR) was used. 
The bacteria were grown to an optical density 
(OD) ~ 1.0 and then diluted to OD = 0.5 in media 
for following survival assays (read at 600 nm 
wavelength). 
 
2.3.2 Media for In vitro evaluation of bacterial 
growth inhibition 
 
M. tuberculosis were grown in Middlebrook 7H9 
supplemented with albumin dextrose complex 
(M-ADC, per liter, 50 grams bovine serum 
albumen fraction V, 20 grams dextrose, 8.5 
grams NaCl, ) (Difco), 0.05% Tween 80 (M-ADC-
Tw) and kanamycin at a final concentration of             
10 µg/ml to select for plasmid maintenance in the 
strains. 
 
2.3.3 In vitro evaluation of compounds 
 
All compounds were dissolved to a final 
concentration of 5 mg/ml in aqueous solution. All 
compound solutions were sterilized by passage 
through 0.22 µm-syringe filters. Survival by 
Optical Density: Four clear 96-well flat bottom 
plates were filled with 108 µl per well of M-ADC-
Tw media supplemented with 10 µg/ml 
kanamycin to maintain luminescence in the 
strain. Each tested compound, as well as 
isoniazid, was added in duplicate wells at 72 µl 
per well at a final concentration of 2 mg/ml. Two-
fold serial dilutions were carried out six times for 
all compounds and isoniazid. The last row of 
wells was maintained without any antibiotic. A 10 
µl per well of M. tuberculosis (bacteria at equal 
concentration in 10 µL for all wells) was added to 
96-well plates to give a final volume of 100 µl per 
well. Plates were incubated at 37°C for 3 days, 7 
days and 14 days.  
 
2.3.4 Measurement of survival by 
luminescence 
 
Four solid white 96-well flat bottom plates were 
prepared as before. Plates were incubated at 
37°C for 3, 7, and 14 days. Luminescence 
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measurements were taken for day 0, 3, 7, and        
14 in the presence of tested compounds                  
[23]. Bacterial luminescence was measured 
measured immediately after addition of 20 µl      
of 5 mM D-luciferin in 0.45 M sodium                        
citrate buffer pH 5.0 (Gold Biotechnology)               
using an EnVision (Perkin Elmer) plate                 
reader. Photon collection time was one second 
per well. 
 
2.4 Synthesis of Compounds 
 
Prior to use, the hydrazine (NH2NH2) must be 
distilled over CaO and NaOH. The anhydrous 
NH2NH2 was collected at 113°C and was stored 
sealed at -20ºC. Hydrazide derivatization: All 
compounds were treated similarly, place 120 mg 
of compound into pyrex open test tube with 64 
microliter of SOCl2. Microwave 3 to 5 minutes 
(avoid over-heating as that will cause 
degradation of the agent), allowed to cool                      
to room temperature. Vacuum pump removal                       
of any unreacted thionyl chloride is 
recommended. Add 400 microliter of anhydrous 
NH2NH2 and microwave at 45 second intervals 
up to five minutes (avoid excess heating                     
during process). Excess hydrazine was                    
removed by pump vacuum at room temperature. 
The derivatives were not heated or allowed                          
to become wet. After thorough drying they                     
are stored dried in air tight containers at                    
-20°C. The presence of the hydrazine group can 
be confirmed by use of FTIR, observing                          
for peaks at 944 cm-1 for hydrazine and 1000       
cm-1 to 1200 cm-1 for C-N stretch, and                       
around 3000 cm-1 to 3500 cm-1 for N-H                       
stretch. Furthermore, the presence of the 
hydrazide group on all final products can                            
be confirmed by the colorimetric protocol                          
and UV-Visible spectrophotometric analysis 
utilizing Gibb’s reagent as described previously 
[24]. Assignments of C-13 peaks for compounds 
A, B, C, and D (ppm): (A) Aromatic carbons                        
C-1 133.4, C-2 128.0, C-3 137.8, C-4 132.6,                    
C-5 128.5, C-6 124.3, 3-methyl carbon 20.9, 
carbonyl carbon 167.3; (B) Aromatic carbons C-1 
133.9, C-2 120.2, C-3 153.2, C-4 124.8, C-5 
129.0, C-6 124.1; carbonyl carbon 167.3; 
carbonyl carbon 168.0 and methyl carbon 16.9; 
(C) Aromatic carbons C-1 133.5, C-2 127.5, C-3 
128.9, C-4 141.2, C-5 128.9, C-6 127.5; carbonyl 
carbon 167.3; methylene bridge carbon 50.5; (D) 
Aromatic carbons C-1 139.6, C-2 128.2, C-3 
123.7, C-4 151.8, C-5 123.7, C-6 128.2; carbonyl 
carbon 167.3. 
3. RESULTS AND DISCUSSION 
 
The investigation and development of novel 
drugs for the treatment of Mycobacterium 
tuberculosis infection is of pressing importance. 
The appearance of multi-drug resistant and 
extensively drug-resistant types of 
Mycobacterium tuberculosis will be a substantial 
problem for clinical intervention. Four hydrazide 
compounds have been synthesized utilizing 
microwave excitation, followed by property 
characterization, then in-vitro testing for bacterial 
growth inhibition.   
 
These four compounds, A, B, C, and D are 
presented for comparison in Fig. 1, with 
molecular structure, IUPAC name, SMILES 
(simplified molecular-input line-entry system 
notation), and formula weight. Notably, each 
compound has a single aromatic ring with a 
hydrazide substituent (-C(O)NHNH2). The range 
of formula weights runs from 150.18 (compound 
A) to 194.19 (compound B). The hydrazide group 
is common to all these compounds, as well as to 
isoniazid (isonicotinylhydrazide), which is an 
antibacterial used as a first-line agent in the 
prevention and treatment of both latent and 
active Mycobacterium tuberculosis infections 
[1,8,9]. For compound A there is a methyl group 
(-CH3) in meta position to the hydrazide group. 
For compound B there is a –OC(O)CH3 group in 
meta position to the hydrazide group. For 
compound C there is a –CH2Cl group in para 
position to the hydrazide group. Lastly, 
compound D has a nitro group –NO2 in para 
position to the hydrazide functional group. The 
substituents of the aromatic ring plays an 
important role in defining molecular properties of 
each compound, which in turn defines the 
efficacy of the compound for clinical application. 
 
Various important properties such as Log P, 
polar surface area, number of oxygen atoms, 
number of nitrogen atoms, number of amine 
groups (-NHn), and molecular volume have been 
determined for each compound, and presented in 
Table 1. One-way ANOVA test of all properties 
for all compounds shown in Table 1 indicate that 
the means of summed numerical values are 
essentially equal (P = .99) [24]. Also, summed 
properties of all compounds have equal medians 
by Kruskal-WalIis test (P = .93) [24]. In addition, 
the correlations of each compound’s properties 
to another are extremely high, with Pearson r 
greater than 0.9700 for all compounds and with 
all properties inclusive (see Table 1).  
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NH2
NH
O
CH3
3-methylbenzohydrazide
Cc1cccc(c1)C(=O)NN
Formula Weight  = 150.18
Compound  A
NH2
NH
O
CH3
O
O
3-(hydrazinylcarbonyl)phenyl acetate
O=C(C)Oc1cc(ccc1)C(=O)NN
Formula Weight  = 194.19
Compound  B
NH2
NH
O
Cl
4-(chloromethyl)benzohydrazide
ClCc1ccc(cc1)C(=O)NN
Formula Weight  = 184.62
Compound  C
NH2
NH
O
N
+O
-
O
4-nitrobenzohydrazide
O=[N+]([O-])c1ccc(cc1)C(=O)NN
Formula Weight  = 181.15
Compound  D
 
Fig. 1. Molecular structures, IUPAC names of 
compounds, SMILES notation, and formula 
weight of compounds A, B, C, and D. Note 
that each compound has one aromatic ring 
one hydrazide group (-C(=O)NHNH2).  
Compound A has a methyl group (-CH3) in the 
meta position to the hydrazide group. For 
compound B the substituent (-O-C(=O)CH3) is 
in the meta position to the hydrazide group.  
However, for compound C the substituent  
(-CH2Cl) is in the para position to the 
hydrazide group; as is (-NO2) for compound D 
 
Molecular properties of compounds A, B, C, D, 
and isoniazid are presented in Table 1.  
Searching for any outliers in numerical values 
utilizing extreme studentized deviate (Grubbs’ 
test) [25], results showed no outliers in values of 
Log P, polar surface area, molecular weight, 
molecular volume, number of oxygen atoms, 
number of nitrogen atoms, and number of 
rotatable bonds. Ranges in numerical values for 
important descriptors such as Log P, polar 
surface area, molecular weight, and molecular 
volume, inclusive of isoniazid, are as follows: -
0.969, to 0.896; 55.12 Angstroms2 to 100.95 
Angstroms2, 137.43 to 194.19, 122.56 
Angstroms3 to 171.25 Angstroms3, respectively. 
 
Notably, all compounds shown in Table 1 show 
zero violations of the Rule of 5, which indicates 
favorable drug absorption and permeation [26]. 
Previous studies have determined that poor 
absorption of drug can occur when there are one 
or more violations of the following parameters, 
known as Rule of 5 [26]: 1) Molecular weight less 
than 500; 2) Log P is less than 5; 3) There is no 
more than 10 hydrogen bond acceptors (nitrogen 
and oxygen atoms); 4) There is no more than 5 
hydrogen bond donors (-OH & -NHn). Outcomes 
for these compounds indicate an opportune 
absorption into the body and efficient membrane 
permeation predicted for compounds A, B, C, 
and D. Oxygen and Nitrogen centered polar 
fragments are considered in determination of 
polar surface area and have been shown to be 
good descriptors for characterizing drug 
absorption, including intestinal absorption, 
bioavailability, Caco-2 permeability and blood-
brain barrier penetration [26]. 
 
Number of rotatable bonds is a simple 
topological parameter considered to be a 
measure of molecular flexibility [26]. Previous 
studies have shown the descriptor of BB 
(Concentration in the brain/Concentration in 
blood) can be accurately estimated and utilized 
to determine if any perspective drug can be 
expected to penetrate into the central nervous 
system (CNS) [27,28]. Studies of drugs known to 
efficiently pierce into the CNS have revealed an 
equation for effectively predicting extent of drug 
penetration, with that equation (1) presented 
below [29]: 
 
 Log BB = -0.0148(PSA) + 0.152(Log P) + 0.139                                         
(1) 
 
Applying equation (1) to PSA and Log P values 
for compounds A, B, C, D, and isoniazid resulted 
in the Log BB (from which BB is determined) 
values for each, are presented in Table 2. 
Interestingly, the BB value (Concentration in 
brain/Concentration in blood) is 0.0966 for first-
line tuberculostat isoniazid, whereas for 
compounds A, B, and C are higher at 0.273, 
0.0977, and 0.288, respectively. Essentially, 
compounds A and C are predicted to have 
significantly greater penetration into the central 
nervous system for treatment of bacterial 
infection due to Mycobacterium tuberculosis. 
This is a very efficacious result, supporting the 
positive potential of these compounds, as well as 
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the study of structure modification that enhances 
the absorption/permeation of tuberculostats.  
Note that compound A has a methyl group 
substituent, compound C has a –CH2Cl 
substituent on the aromatic ring (see Fig. 1).  
Small molecules have a greater chance to 
penetrate into the central nervous system [27], 
and molecules having a molecular weight less 
than 400 have greater penetration [28]. 
 
Tuberculous meningitis is associated with high 
morbidity and mortality with incidence of CNS 
tuberculosis directly proportional to the 
prevalence of tuberculous infection in general 
[30]. 
 
Bioactivity scores for compounds A, B, C, and D 
also indicate that these molecular scaffolds have 
structures similar to optimal drug-likeness in six 
major categories defined in Table 3. This 
strategy leads to drug-likeness score, with focus 
on particular drug classes and development of 
specific activity score for each of these classes.  
Drug-likeness scores assist in determining which 
drug should be synthesized and screened [31]. 
Drug-likeness is often considered a qualitative 
property of chemicals which is widely integrated 
into the early stages of lead and drug discovery 
[32]. Methods that estimate drug-likeness are 
valuable in the early stages of lead discovery, 
and can be used to filter out compounds with 
undesirable properties from screened libraries of 
candidates and to prioritize candidates from 
primary screens [32]. The goal is the 
development of orally available drugs but these 
approaches are also useful to optimize drug-like 
pharmacokinetic properties [32]. Optimal ranges 
for each drug category are indicated in the first 
column labeled Category. 
 
Note that compounds A, B, C, and D all show 
bioactivity scores falling within the optimal ranges 
for drug categories GPCR ligand, ion channel 
modulator, kinase inhibitor, protease inhibitor, 
and enzyme inhibitor. Only in the category of 
nuclear receptor ligand that compounds A and C 
fall slightly outside the optimal range, while 
compounds B and D fall within the optimal range.  
This approach is known to provide useful 
evaluation of the drug structure as to whether 
there is consistency in scaffolding and similarity 
to related clinical drugs.   
   
Table 1. Comparison of properties (Isoniazid and compounds A, B, C, and D) 
    
Property Isoniazid Compound 
A 
Compound  
B 
Compound 
C 
Compound  
D 
Log P -0.969 0.745 0.372 0.896 0.279 
Polar Surface Area 
(Angstroms2) 
68.01 55.12 81.43 55.12 100.95 
Number of Atoms 10 11 14 12 13 
Molecular Weight 137.43 150.18 194.19 184.63 181.15 
Number of Oxygen Atoms 1 1 3 1 3 
Number of Nitrogen Atoms 3 2 2 2 3 
Number of -OH & -NHn 2 2 2 2 2 
Number Rotatable Bonds 1 1 3 2 2 
Molecular Volume  
(Angstroms3) 
122.56 143.28 171.25 157.06 150.05 
Violations Rule of 5 0 0 0 0 0 
Dipole 
(Debye) 
4.835 4.947 2.522 5.614 3.481 
 
Table 2. Penetration into central nervous system based on Log BB 
 
Compound Log BB BB = Cbrain/Cblood 
A -0.563 0.273 
B -1.01 0.0977 
C -0.541 0.288 
D -1.31 0.0487 
Isoniazid -1.02 0.0966 
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The scores for compounds A, B, C, and                             
D indicate favorable drug-likeness within                       
the six categories examined. These                          
favorable outcomes show these four compounds 
to have potential for successful drug                
candidates.  
 
Compounds A, B, C, and D were placed                      
into tissue culture at various concentrations,    
then subjected to bacterial presence to 
determine their effects on bacterial growth.  
Similarly, this was accomplished with first-line 
tuberculostat isoniazid, for comparison to novel 
compounds. 
Results that are presented in Fig. 2, show clearly 
that all four novel compounds A, B, C, D, as well 
as isoniazid very strongly inhibit the growth of 
bacteria (more than 85%) at concentrations less 
than 50 micrograms per milliliter. Near complete 
bacterial inhibition is accomplished at all 
concentrations greater than 100 micrograms per 
milliliter. These results were observed at day 3 
and day 14 (see Fig. 2).   
 
Table 3. Bioactivity scores of compounds 
 
Category (Range) Compound A Compound B Compound C Compound D 
GPCR ligand 
(-1.50 to 0.50) 
-1.40 -1.04 -1.41 -1.31 
Ion channel modulator 
(-2.00 to 0.50) 
-1.59 -1.13 -1.43 -1.22 
Kinase inhibitor 
(-2.00 to 0.5) 
-1.29 -1.02 -1.49 -1.16 
Nuclear receptor ligand 
(-2.00 to 0.50) 
-2.04 -1.24 -2.23 -1.76 
Protease inhibitor 
(-2.00 to 0.50) 
-1.25 -0.83 -0.84 -1.15 
Enzyme inhibitor 
(-1.50 to 0.50) 
-0.84 -0.48 -0.66 -0.73 
 
 
 
Fig. 2. Inhibition of bacterial growth induced by compounds A, B, C, and D; compared to 
isoniazid at day 3 and day 14. Bacterial presence measured by luminescence. There is very 
substantial inhibition of growth at concentrations less than 100 micrograms per milliliter.  
Essentially complete inhibition occurs at higher concentrations 
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Therefore, it can be concluded that the 
suppression of bacteria occurs soon after 
administration and follows strongly and 
effectively for time period reaching from day 3 of 
administration to day 14 (two weeks after). 
Following bacterial inhibition by luminescence 
provides accurate information to the extent of 
microbial suppression and conveys a measure of 
the bacterial metabolic activity, that in turn, 
suggests that compounds A, B, C, and D rapidly 
shuts down metabolism preceding bacterial 
death. 
 
Similarly, when measured by colony-forming unit 
(unit to estimate the number of viable bacteria) 
all four compounds A, B, C, and D substantially 
reduces bacteria survival (see Fig. 3). The level 
of bacterial inhibition is similar to that induced by 
first-line tuberculostat isoniazid. Bacterial 
inhibition greater than 85% is accomplished at 
concentrations less than 50 micrograms per 
milliliter. This very strong growth suppression is 
sustained at concentrations greater than 100 
micrograms per milliliter. Inhibition of growth as 
measured by colony-forming units is very strong 
and apparent soon after exposure at day 3 and 
extends to day 14 (two week time period). These 
results show clearly the very strong inhibitory 
effect of compounds A, B, C, and D on the 
growth of this deadly bacteria. 
 
The design of new drugs for use in the ongoing 
battle against the deadly infections of 
Mycobacterium tuberculosis is a very necessary 
endeavor. The appearance of multiple drug 
resistant, extensively drug resistant, and totally 
drug resistant bacterial types is a very strong 
concern. Numerous nations are particularly 
prone to have problems of containment due to 
poor communication, poor transportation,                 
poor economy, and lower quality of medical 
support. 
 
 
 
Fig. 3. Inhibition of bacterial growth induced by compounds A, B, C, and D; compared to 
isoniazid. Bacterial inhibition measured by colony-forming units (CFU). There is substantial 
inhibition of growth at concentrations less than 100 micrograms per milliliter. Essentially 
complete inhibition occurs at higher concentrations 
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The development of new drugs will assist in 
containment of bacterial outbreaks and 
proliferation. The compounds presented in this 
study are shown to substantially suppress 
bacterial proliferation and possess properties 
highly favorable in drug-likeness, absorption, and 
bacterial inhibition. 
 
4. CONCLUSION 
 
Four novel compounds that are presented here 
have a single hydrazide group covalently bonded 
to a single aromatic ring. In addition, there 
various substituents in the meta or para position 
to the hydrazide group. Molecular properties 
were calculated and showed values statistically 
comparable to first-line tuberculostat isoniazid.  
All four compounds A, B, C, and D showed zero 
violations of the Rule of 5, indicating these 
compounds have properties enabling favorable 
absorption into the body and membrane 
penetration. Compounds A and C show potential 
for substantially greater penetration into the 
central nervous system than that for isoniazid, on 
order to treat bacterial infection by 
Mycobacterium tuberculosis. All four compounds 
showed bioactivity scores within the optimal 
ranges for five major categories of clinical drugs. 
Substantial bacterial growth inhibition was 
accomplished by all four novel compounds and 
to a level comparable to isoniazid. Measured by 
luminescence and colony forming units, 
compounds A, B, C, and D initiated greater than 
85% growth inhibition of bacteria at 
concentrations less than 50 micrograms per 
milliliter.  Compounds A, B, C, and D showed 
very strong bacterial growth inhibition and 
molecular properties favorable for drug 
absorption, drug-likeness, and penetration into 
the central nervous system. The investigation 
and design of novel drugs to treat infections of 
Mycobacterium tuberculosis is a highly desirable 
endeavor to assure continued effective clinical 
treatment of this deadly microbe. 
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